760 related articles for article (PubMed ID: 27215744)
1. Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV.
Wecker T; Ehlken C; Bühler A; Lange C; Agostini H; Böhringer D; Stahl A
Br J Ophthalmol; 2017 Mar; 101(3):353-359. PubMed ID: 27215744
[TBL] [Abstract][Full Text] [Related]
2. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.
Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC
BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516
[TBL] [Abstract][Full Text] [Related]
3. Individualized treat-and-extend regime for optimization of real-world vision outcome and improved patients' persistence.
Volkmann I; Knoll K; Wiezorrek M; Greb O; Framme C
BMC Ophthalmol; 2020 Mar; 20(1):122. PubMed ID: 32228517
[TBL] [Abstract][Full Text] [Related]
4. Relationship Between Visual Acuity and Retinal Thickness During Anti-Vascular Endothelial Growth Factor Therapy for Retinal Diseases.
Ou WC; Brown DM; Payne JF; Wykoff CC
Am J Ophthalmol; 2017 Aug; 180():8-17. PubMed ID: 28549848
[TBL] [Abstract][Full Text] [Related]
5. COMPLIANCE AND ADHERENCE OF PATIENTS WITH DIABETIC MACULAR EDEMA TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN DAILY PRACTICE.
Weiss M; Sim DA; Herold T; Schumann RG; Liegl R; Kern C; Kreutzer T; Schiefelbein J; Rottmann M; Priglinger S; KortUEm KU
Retina; 2018 Dec; 38(12):2293-2300. PubMed ID: 29068914
[TBL] [Abstract][Full Text] [Related]
6. Quantifying metamorphopsia in patients with diabetic macular oedema and other macular abnormalities.
Achiron A; Lagstein O; Glick M; Gur Z; Bartov E; Burgansky-Eliash Z
Acta Ophthalmol; 2015 Dec; 93(8):e649-53. PubMed ID: 25899144
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: a systematic review and meta-analysis.
Low A; Faridi A; Bhavsar KV; Cockerham GC; Freeman M; Fu R; Paynter R; Kondo K; Kansagara D
Br J Ophthalmol; 2019 Apr; 103(4):442-451. PubMed ID: 30409915
[TBL] [Abstract][Full Text] [Related]
8. [What can anti-VEGF therapy achieve in clinical routine? : Effectiveness of anti-VEGF therapy in patients with macular diseases in clinical routine on 1492 eyes in Austria].
Wiesinger K; Reinelt P; Ennemoser A; Edelmayr M; Schönherr U
Ophthalmologe; 2017 Jul; 114(7):639-645. PubMed ID: 27815675
[TBL] [Abstract][Full Text] [Related]
9. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.
Avery RL; Castellarin AA; Steinle NC; Dhoot DS; Pieramici DJ; See R; Couvillion S; Nasir MA; Rabena MD; Maia M; Van Everen S; Le K; Hanley WD
Retina; 2017 Oct; 37(10):1847-1858. PubMed ID: 28106709
[TBL] [Abstract][Full Text] [Related]
10. Impact of initial visual acuity on anti-VEGF treatment outcomes in patients with macular oedema secondary to retinal vein occlusions in routine clinical practice.
Wai KM; Khan M; Srivastava S; Rachitskaya A; Silva FQ; Deasy R; Schachat AP; Babiuch A; Ehlers JP; Kaiser PK; Yuan A; Singh RP
Br J Ophthalmol; 2017 May; 101(5):574-579. PubMed ID: 27503394
[TBL] [Abstract][Full Text] [Related]
11. Machine Learning Can Predict Anti-VEGF Treatment Demand in a Treat-and-Extend Regimen for Patients with Neovascular AMD, DME, and RVO Associated Macular Edema.
Gallardo M; Munk MR; Kurmann T; De Zanet S; Mosinska A; Karagoz IK; Zinkernagel MS; Wolf S; Sznitman R
Ophthalmol Retina; 2021 Jul; 5(7):604-624. PubMed ID: 33971352
[TBL] [Abstract][Full Text] [Related]
12. Long-term dynamic changes and influencing factors of corneal morphology after multiple intravitreal injections of anti-VEGF drugs.
Qi Y; Li C; Ye S; Zhang Z; Li S; Zhang L
Medicine (Baltimore); 2024 Apr; 103(17):e37937. PubMed ID: 38669379
[TBL] [Abstract][Full Text] [Related]
13. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).
Wu L; Martínez-Castellanos MA; Quiroz-Mercado H; Arevalo JF; Berrocal MH; Farah ME; Maia M; Roca JA; Rodriguez FJ;
Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):81-7. PubMed ID: 17674014
[TBL] [Abstract][Full Text] [Related]
14. Retinal function determined by flicker ERGs before and soon after intravitreal injection of anti-VEGF agents.
Terauchi G; Shinoda K; Sakai H; Kawashima M; Matsumoto CS; Mizota A; Miyake Y
BMC Ophthalmol; 2019 Jun; 19(1):129. PubMed ID: 31208350
[TBL] [Abstract][Full Text] [Related]
15. Longer-Term Anti-VEGF Therapy Outcomes in Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Vein Occlusion-Related Macular Edema: Clinical Outcomes in 130 247 Eyes.
Ciulla TA; Hussain RM; Taraborelli D; Pollack JS; Williams DF
Ophthalmol Retina; 2022 Sep; 6(9):796-806. PubMed ID: 35381391
[TBL] [Abstract][Full Text] [Related]
16. One- and two-year visual outcomes from the Moorfields age-related macular degeneration database: a retrospective cohort study and an open science resource.
Fasler K; Moraes G; Wagner S; Kortuem KU; Chopra R; Faes L; Preston G; Pontikos N; Fu DJ; Patel P; Tufail A; Lee AY; Balaskas K; Keane PA
BMJ Open; 2019 Jun; 9(6):e027441. PubMed ID: 31230012
[TBL] [Abstract][Full Text] [Related]
17. Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in Indian patients with retinal vein occlusion, age-related macular degeneration, and diabetic macular edema.
Kelkar A; Webers C; Shetty R; Kelkar J; Labhsetwar N; Pandit A; Malode M; Tidke S
Indian J Ophthalmol; 2020 Oct; 68(10):2143-2147. PubMed ID: 32971626
[TBL] [Abstract][Full Text] [Related]
18. Ziv-aflibercept in macular disease.
Mansour AM; Al-Ghadban SI; Yunis MH; El-Sabban ME
Br J Ophthalmol; 2015 Aug; 99(8):1055-9. PubMed ID: 25677668
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal ziv-aflibercept for the treatment of choroidal neovascularisation associated with conditions other than age-related macular degeneration.
Braimah IZ; Stewart M; Videkar C; Dedhia CJ; Chhablani J;
Br J Ophthalmol; 2017 Sep; 101(9):1201-1205. PubMed ID: 28119292
[TBL] [Abstract][Full Text] [Related]
20. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations.
Algvere PV; Steén B; Seregard S; Kvanta A
Acta Ophthalmol; 2008 Aug; 86(5):482-9. PubMed ID: 18162062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
